Skip to main content

Month: April 2022

RBR and Aite-Novarica Group Join Forces

Merger creates the preeminent global research and advisory firm focused on the financial services and retail technology sectors Boston and London, April 12, 2022 (GLOBE NEWSWIRE) — RBR, the leading provider of strategic research and data on banking automation, cards, payments, and retail technology, and Aite-Novarica Group (ANG), an advisory firm providing mission-critical insights on technology, regulations, markets, and operations to banks, payments providers, insurers, and securities firms today announced their intention to merge. “RBR has built both a world-class research and data collection reputation and deep relationships with its customers,” says Kurt Reisenberg, CEO of the combined company. “Combining RBR’s unrivalled data products and research capabilities with Aite-Novarica Group’s market-leading insights and advisory...

Continue reading

Option Care Health Completes Acquisition of Specialty Pharmacy Nursing Network Inc.

BANNOCKBURN, Ill., April 12, 2022 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the largest independent provider of home and alternate site infusion services in the United States, announced today that it has completed the acquisition of Specialty Pharmacy Nursing Network Inc. (“SPNN”). SPNN is a national leader in providing highly skilled specialty nursing resources across a broad portfolio of healthcare providers with over 400 nurses across the country. The acquisition builds upon the market-leading nursing platform Option Care Health established with its acquisition of Infinity Infusion Nursing LLC (“Infinity”) to expand access to clinical resources across the United States. Leveraging Option Care Health’s national infrastructure, the acquisitions of Infinity and SPNN establish a more comprehensive...

Continue reading

KYN Capital Group Announces Acquisition of BW Property Management

CARSON CITY, NV, April 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – KYN Capital Group (OTC: KYNC) is pleased to announce that BW Property Management Group, the developer of Pay.How, has been acquired by KYN Capital Group. KYN Capital has agreed to acquire BW Management effective immediately. As such, BW Management will become a wholly owned subsidiary of KYN Capital Group. This milestone achievement for KYN Capital Group adds a revenue positive company to its portfolio. During the 1st Quarter of 2022, Pay.How generated positive revenue and promising metrics on its platform. Revenue is expected to grow by as much as 300% by end of year 2022. Pay.How expects to remain in beta through the end of second quarter although several key features are currently available. Below are some key beta metrics from the 1st Quarter:Home sales...

Continue reading

Newtek Small Business Finance Retains Position as Largest Non-Bank SBA 7(a) Lender

BOCA RATON, Fla., April 12, 2022 (GLOBE NEWSWIRE) — Newtek Business Services Corp., (NASDAQ: NEWT), an internally managed business development company (“BDC”), today announced that Newtek Small Business Finance (“NSBF”) retained its position as the largest non-bank lender (with PLP status) licensed by the SBA under the federal Section 7(a) loan program, based on loan approval dollar volume as of March 31, 2022. In addition, NSBF was ranked as the 2nd largest SBA 7(a) lender, including banks, by loan approval dollar volume as of March 31, 2022. Barry Sloane, President, Chairman and CEO Newtek commented, “We are thrilled to have retained our position as the top ranked non-bank SBA 7(a) lender among banks, and second largest SBA 7(a) lender including banks. Remaining a top SBA 7(a) lender is testament to our continued focus and inherent...

Continue reading

SANUWAVE Announces New Board Leadership

SANUWAVE announces addition of three new board members this quarter SUWANEE, GA, April 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWire SANUWAVE Health, Inc. (SNWV), a leading provider of next-generation wound care products, today announced three new board members will join as one departs. “We are excited to expand our board with three new members who will help us reach new heights by bringing diverse expertise and insight to our work,” said SANUWAVE CEO & Chairman of the Board Kevin A. Richardson, II. “We anticipate 2022 being a year of growth and opportunity and we have worked diligently to ensure SANUWAVE’s board and leadership represents a variety of experts that will support the progression and evolution of the company.” The new board members Ian Miller, Jeffrey Blizard, and Jim Tyler will begin their terms in Q2 2022....

Continue reading

Pegasus Acquires USA Uranium Project

Pegasus Signs Option Agreement to Acquire 147 Lode Mining Claims in South Dakota, USA Covering a Non-NI 43-101 Compliant Historical Measured and Indicated Resource Containing 2,379,990 Lbs. U3O8 and a Historical Potential Resource Containing 1,440,000 Lbs. U3O8 VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) — Pegasus Resources Inc. (TSX-V: PEGA: Frankfurt – OQS2, OTC/Pink Sheet symbol: SLTFF) (the “Company” or “Pegasus”) is pleased to announce the acquisition of 147 lode mining claims (approximately 3,037 acres) located on lands managed by United States Forest Service in Fall River County, South Dakota. Claims were optioned from Cowboy Exploration and Development, a Wyoming-registered LLC in an all-cash deal, US$1,500,000 for 100% ownership payable over three years (subject to TSX approval). Mineralization is hosted...

Continue reading

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its Phase 2 IOB-022 / KN-D38 trial (NCT05077709). The IOB-022 / KN-D38 trial seeks to evaluate IO Biotech’s lead candidate, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in previously untreated patients with three different tumor types in the first line setting —NSCLC, squamous cell carcinoma of the head and neck (SCCHN), and urothelial bladder cancer (mUBC). “Initiating this study with IO102-IO103 further progresses our late-stage development program,”...

Continue reading

Halo Elevate Officially Hits Shelves at Pet Supplies Plus

Halo’s Ground-Breaking Brand of Super Premium, Natural Pet Food will be Available at 600+ Pet Supplies Plus Locations Beginning in Early April NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) — Better Choice Company (NYSE American: BTTR), a pet health and wellness company, announced today that its new Halo Elevate brand is officially on shelf at Pet Supplies Plus, the third-largest pet specialty retailer in the United States. Pet Supplies Plus operates more than 600 locations across the United States and has a presence in 36 states and counting. “We are excited to introduce Halo Elevate, our new ground-breaking brand of super-premium, natural pet food, to Pet Supplies Plus customers in early April. Pet Supplies Plus’s commitment to delivering high-quality pet food and products makes them an ideal retail partner for Halo Elevate, and we...

Continue reading

Armstrong World Industries to Report First-Quarter 2022 Results April 26

LANCASTER, Pa., April 12, 2022 (GLOBE NEWSWIRE) — Armstrong World Industries, Inc. (NYSE:AWI), a leader in the design, innovation and manufacture of commercial and residential ceiling, wall and suspension system solutions, will release its first-quarter 2022 results before the market opens on Tuesday, April 26 and host a conference call to discuss these results at 10:00 a.m. ET. Conference call and webcast information as well as the accompanying presentation will be available on the Investor Relations page at ArmstrongWorldIndustries.com. To participate by telephone, please dial:(877) 312-9198 (U.S./Canada) (631) 291-4622 (International) Conference ID: 6367957A replay of the event will be available via webcast on the Investor Relations page at ArmstrongWorldIndustries.comContacts  Investors:  Theresa Womble, tlwomble@armstrongceilings.com...

Continue reading

Panbela Announces Poster Presentation at American Association for Cancer Research:

The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer announces a poster presentation highlighting the results for SBP-101 as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), taking place April 8-13, 2022. The work reflects the Company’s ongoing collaboration with Johns Hopkins University School of Medicine. “The treatment of C57Bl/6 mice injected with VDID8+ ovarian cancer with SBP-101 was observed to significantly prolong survival and decrease overall tumor burden,” said Jennifer K....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.